Biomaterials-based cancer vaccine development for precision cancer medicine
발표자
()
초록
내용
Tumors develop physical and chemical barriers against antitumor functions of cytotoxic T lymphocytes (CTLs), therefore, it is necessary to disrupt the immune-resistant TME to exploit the full therapeutic potential of CTLs against tumors, but such heterogeneity and complexity of TME pose numerous challenges for the field to overcome. In this talk, a new paradigm of cancer treatment with an emphasis on a personalized cancer vaccine will be introduced and messenger RNA (mRNA) will be highlighted as a next-generation therapeutics beyond the vaccine platform. Then various immunoengineering strategies to manipulate antitumor T cells in TME will be introduced including messenger RNA (mRNA)-based cancer vaccine development and in situ vaccination strategies. To this end polysaccharide biopolymer as a pathogen-associated molecular pattern was engineered to have a unique nanostructure, termed nano-PAMP, to promote robust immune response and elicit antitumor immune responses.